$ 5,943.20
Details
The Human Tumor Necrosis Factor beta (Hu TNFβ) ELISA quantitates Hu TNFβ in human serum, plasma, urine, synovial fluid, amniotic fluid, cell culture supernatants, or other body fluids. The assay will exclusively recognize both natural and recombinant Hu TNFβ. Principle of the method The Human TNFβ solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the binding of the second (detector) antibody to the target on a different epitope from the capture antibody. An antibody conjugated with enzyme binds the formed sandwich. After incubation and washing steps to rid the microplate of unbound substances, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.Tumor Necrosis Factor (TNF) was originally discovered as a serum protein with necrotizing effects on certain transplantable mouse tumors in vivo and cytotoxic effects against some transformed cells in vitro. The TNF family consists of two proteins designated TNF-alpha, also called cachectin, and TNF-beta, also called lymphotoxin. Soluble TNF-beta is a T-cell derived glycoprotein of 25 kD mainly produced by activated lymphocytes. TNF-beta is 28 % structurally homologous with the macrophage produced non-glycoprotein TNF-alpha. TNF-beta is induced in an antigen-specific MHC restricted fashion from class I and class II restricted T cells. Viral infection is also associated with TNF-beta production by lymphoid cells. TNF-beta has several effects on target cells including killing, growth stimulation, induction of adhesion molecule (ICAM-1) expression, and induction of differentiation. The mechanisms of TNF-beta effects involve receptor binding and internalization and several sequelae including changes in prostaglandins and chromosome integrity. TNF-beta participates in tumor immunity, and it has been reported to inhibit carcinogenesis as well as growth of some tumors in vivo.
